Navigation Links
Treating bone loss in breast cancer survivors
Date:9/15/2009

MAYWOOD, Il. A key statistic that consumer groups and the media often use when compiling hospital report cards and national rankings can be misleading, researchers report in a new study.

The statistic is called the mortality index. A number above 1.0 indicates a hospital had more deaths than expected within a given specialty. Lower than 1.0 means there were fewer than the expected number of deaths.

The study by Loyola University Health System researchers in the Journal of Neurosurgery illustrates how the mortality index can be misleading in at least two major specialties -- neurology and neurosurgery. The index fails to take into account such factors as whether a hospital treats complex cases transferred from other hospitals or whether a hospital treats lower-risk elective cases or higher-risk non-elective cases.

"A hospital with a lower mortality index may not be a better hospital for patient care, but rather a place where the patient mix has been refined or limited," said senior author Dr. Thomas Origitano, chairman of the Department of Neurological Surgery, Loyola University Stritch School of Medicine.

There is no "definitive or reliable source for rating the quality of overall neurosurgical care," Origitano and colleagues wrote in the Journal of Neurosurgery, published by the American Association of Neurological Surgeons.

Researchers examined neurosurgical mortality data from 103 academic medical centers in the University HealthSystem Consortium. Hospitals with the worst mortality index tended to be Level 1 trauma centers with busy emergency rooms and a high percentage of Medicaid patients.

A Level 1 trauma center with a busy ER is more likely to treat severe and complex cases such as head and spinal injuries from car accidents, injuries from falls or gunshot wounds. And the reason a high percentage of Medicaid patients is associated with a high mortality index is likely because Medicaid patients are more likely to have "poor access to medical care, are poorly educated in health and hygiene, are uninsured and present only once their symptoms have become severe," researchers wrote.

The study also found that in hospitals with the lowest mortality index, at least 87 percent of the neurosurgical cases were elective in nature. Elective surgery includes cases such as back surgery or decompression of a pinched nerve. Patients deemed to be at too high a risk do not undergo the surgery.

By contrast, non-elective surgery for such conditions as head injuries and spine infections generally has to be done even when the risks are high.

Researchers cited several other problems with rating systems. For example, report cards typically lump neurology and neurosurgery into one category, neurosciences. "Although both services treat many of the same pathological processes, their performance at any given institution is by no means shared," researchers wrote. "This can be misleading if the neurology aspects of the rating system misrepresent the neurosurgical service or vice versa."

Another common practice is using reputation as one of the main ranking criteria. This practice "is at best subjective," researchers wrote.

Researchers wrote that misleading information in report cards and rakings "may falsely direct patients and their families to hospitals providing a lower level of neurosurgical care, or direct them away from hospitals providing a high level of neurosurgical care."


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related biology news :

1. Single host gene may hold key to treating both ebola and anthrax infections
2. Test helps in fight against lung infections and for treating other life-threatening infections
3. Glutamine supplements show promise in treating stomach ulcers
4. New hope for advances in treating malaria
5. Cold and brown fat raise the prospect of a new method of treating obesity
6. New drug shows promise in treating drug-resistant prostate cancer
7. NC State researchers find soy may aid in treating canine cancers
8. New medications show promise in treating drug-resistant prostate cancer
9. Antibody key to treating variant CJD, scientists find
10. Studies point to novel target for treating arrhythmias
11. World breakthrough in treating premature babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
(Date:11/15/2016)... , Nov 15, 2016 Research and Markets ... Forecast to 2021" report to their offering. ... ... 16.18 Billion by 2021 from USD 6.21 Billion in 2016, growing ... Growth of the bioinformatics market is driven by the growing ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
(Date:12/8/2016)... Portland, Oregon (PRWEB) , ... December 08, 2016 ... ... modules and the FrontPanel SDK that provide essential device-to-computer interconnect using USB or ... do not require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module ...
(Date:12/8/2016)... ... 08, 2016 , ... KBioBox llc announced today the launch ... developed a sophisticated “3 click” gene dditing off target analysis program and a ... https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016  Soligenix, ... late-stage biopharmaceutical company focused on developing and commercializing ... an unmet medical need, announced today the long-term ... with SGX942 (dusquetide), a first-in-class Innate Defense Regulator ... in head and neck cancer patients undergoing chemoradiation ...
Breaking Biology Technology: